{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red255\green255\blue174;
\red183\green242\blue206;
\red37\green37\blue37;
\red33\green33\blue33;
\red255\green210\blue183;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red14\green86\blue140;
\red255\green255\blue102;
\red80\green80\blue80;
\red51\green51\blue51;
\red56\green124\blue43;
\red204\green204\blue204;
\red151\green151\blue151;
\red0\green114\blue54;
\red112\green112\blue112;
\red106\green144\blue39;
\red21\green137\blue21;
\red255\green248\blue96;
\red247\green247\blue247;
\red239\green122\blue2;
\red107\green107\blue106;
\red232\green233\blue232;
\red249\green249\blue249;
\red249\green250\blue251;
\red228\green231\blue232;
\red254\green254\blue0;
\red181\green79\blue104;
\red233\green233\blue233;
\red203\green203\blue203;
\red127\green127\blue127;
\red245\green245\blue245;
\red71\green120\blue194;
\red190\green190\blue252;
\red255\green194\blue211;
\red187\green187\blue187;
\red242\green242\blue242;
\red240\green240\blue240;
\red105\green105\blue105;
\red204\green255\blue255;
\red236\green236\blue236;
\red61\green61\blue61;
\red188\green41\blue30;
\red190\green237\blue228;
\red229\green243\blue255;
\red179\green218\blue255;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red208\green208\blue208;
\red227\green227\blue227;
\red255\green191\blue101;
\red149\green246\blue220;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red118\green118\blue118;
\red172\green172\blue172;
\red9\green56\blue84;
\red212\green212\blue212;
\red102\green102\blue102;
\red240\green248\blue255;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 Source Sans Pro;}{
\f6 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid-2064816887\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid-2044611882}
}
{\*\listoverridetable
{\*\listoverride{\listid-2044611882\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Esoterix Genetic Laboratories LLC v. Qiagen Inc., 133 F.Supp.3d 349 (2015)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_17}{\*\bkmkend co_document_17}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I02566100668f11e5a966f97caf3cb288_Target}{\*\bkmkend I02566100668f11e5a966f97caf3cb288_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_17}{\*\bkmkend co_readingModeKC_17}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_17}{\*\bkmkend co_readingModeCitatorFlag_17}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I02566100668f11e5a966f97caf3cb288&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_17}{\*\bkmkend co_readingModeNegativeTreatment_17}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Declined to Follow by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/Ic8780dc085d811e6b63ccfe393a33906/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DIc8780dc085d811e6b63ccfe393a33906%26ss%3D2037262855%26ds%3D2039879591%26origDocGuid%3DI02566100668f11e5a966f97caf3cb288&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=25ba8d0a9e13498ba250f84a7948bf66&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Front Row Technologies, LLC v. NBA Media Ventures, LLC
}
{\b0 \cf28 \f2 \i0 \fs16 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
D.N.M., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
August 30, 2016
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
133 F.Supp.3d 349
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. Massachusetts.
\par 
}
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
ESOTERIX GENETIC LABORATORIES LLC, Plaintiff,
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
QIAGEN INC. and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(4296691894)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf28 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Qiagen Manchester, Ltd.
}}}
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendants.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Civil Action No. 14-cv-13228-ADB
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed September 25, 2015
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_17}{\*\bkmkend co_synopsis_17}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Assignee commenced action against licensee, alleging infringement of patent, unfair or deceptive trade practices, breach of contract, and breach of the duty of good faith and fair dealing. Licensee moved to dismiss.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The District Court, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0358384799&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Burroughs
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, J., held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent was not eligible for patent protection, and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
royalties could be recoverable under breach of contract theory.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Motion granted in part and denied in part.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_17}{\*\bkmkend co_attorneysAndLawFirms_17}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_350_17}{\*\bkmkend co_pp_sp_7903_350_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*350
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328459001&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Beth D. Jacob
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0357585001&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Clifford Katz
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0413983701&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jaclyn M. Metzinger
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0171594501&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Robert I. Steiner
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Kelley Drye & Warren LLP, New York, NY, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0168974201&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
James M. Campbell
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0338485601&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher Robert Howe
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Campbell, Campbell, Edwards & Conroy, PC, Boston, MA, for Plaintiff.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0414167501&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Daniel A. Nadel
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0327861901&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Marc Segal
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328678801&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Robert R. Baron
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Ballard Spahr LLP, Philadelphia, PA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0217027701&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Peter E. Ball
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0357398301&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ryan M. Cunningham
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Sally & Fitch LLP, Boston, MA, for Defendants.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_17}{\*\bkmkend co_opinion_17}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8103732c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8103732c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8304251c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8304251c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8304251c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8304251c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb800 
MEMORANDUM AND ORDER
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0358384799&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
BURROUGHS
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, District Judge
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8309072c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8309072c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8309072c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8309072c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. INTRODUCTION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff Esoterix Genetic Laboratories LLC (\u8220\'3fEsoterix\u8221\'3f) brings this action against Defendants Qiagen Inc. and Qiagen Manchester, LTD. (collectively, \u8220\'3fQiagen\u8221\'3f), alleging that Qiagen has exceeded the scope of a license agreement and thereby infringed upon Esoterix\rquote s patent rights. Esoterix\rquote s Amended Complaint [ECF No. 7 (\u8220\'3fCompl.\u8221\'3f) ], alleges claims for patent infringement (Count I); violation of Massachusetts General Laws Ch. 93A (Count II); breach of contract (Count III); and breach of the duty of good faith and fair dealing (Count IV).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_351_17}{\*\bkmkend co_pp_sp_7903_351_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*351
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Before the Court is Qiagen\rquote s Motion to Dismiss the Amended Complaint pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, for failure to state a claim upon which relief may be granted. [ECF No. 26.] Qiagen argues that the patent-in-suit, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,294,468
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, is invalid because it purports to cover an unpatentable \u8220\'3flaw of nature\u8221\'3f and that, as a result, Esoterix\rquote s patent infringement claim is not viable, and all of Esoterix\rquote s state-law claims must also be dismissed. For the reasons discussed in this Memorandum and Order, Qiagen\rquote s Motion to Dismiss is allowed in part and denied in part.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id831f001c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id831f001c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id831f001c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id831f001c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. FACTS ALLEGED IN THE COMPLAINT
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Esoterix is the assignee of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,294,468 (the \u8220\'3f\rquote 468 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, titled \u8220\'3fMethod to Determine Responsiveness of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to Epidermal Growth Factor Receptor Targeting Treatments.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; Compl. \u182\'3f\u182\'3f 21-24.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012037262855_ID0EYEAG_17}{\*\bkmkend co_fnRef_B00012037262855_ID0EYEAG_17}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012037262855_17" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims a method for determining whether particular types of pharmaceutical drugs are likely to be effective in treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic30437c8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
non-small cell lung cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient, based on the presence or absence of certain nucleotide variances in the patient\rquote s gene. More specifically, the inventors discovered that there is a positive correlation between the existence of particular naturally-occurring nucleotide variations on a person\rquote s epidermal growth factor receptor (\u8220\'3fEGFR\u8221\'3f) gene, and the likelihood that specific pharmaceutical compounds (namely, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) will be effective in treating non-small 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic75605b3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
lung cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in that person. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 519:44-520:49. The patent application was filed on December 4, 2005, and the U.S. Patent Office issued the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on November 13, 2007.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Previously, all right, title, and interest in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was owned by non-party Genzyme Corporation (\u8220\'3fGenzyme\u8221\'3f). In 2008, Genzyme entered into a License Agreement (the \u8220\'3fLicense Agreement\u8221\'3f) with non-party DxS, Ltd. (\u8220\'3fDxS\u8221\'3f). The License Agreement granted DxS a non-exclusive license to manufacture and sell certain products utilizing the
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \lquote 468
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Patent, in exchange for royalty payments, among other terms and conditions. Compl. \u182\'3f\u182\'3f 18, 25-32. In or around September 2009, DxS was acquired by a Qiagen entity, and Qiagen therefore assumed DxS\rquote s rights and obligations as licensee under the License Agreement. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 20. In December 2010, Genzyme sold certain assets (including all its rights to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, as well as its rights as licensor under the License Agreement) to Laboratory Corporation of America Holdings (\u8220\'3fLabCorp\u8221\'3f). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 2, 21. LabCorp, in turn, created Esoterix as a wholly-owned subsidiary, to control the purchased assets, and Esoterix now holds all right, title, and interest in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and claims to be the successor-in-interest to Genzyme under the License Agreement. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 23-24.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The gravamen of Esoterix\rquote s claims in this case is that Qiagen exceeded the scope of the license, and breached certain promises made in the License Agreement. Notably, the License Agreement only allowed Qiagen to sell certain types of products at certain times, and it drew a key distinction between \u8220\'3fLicensed Products\u8221\'3f and \u8220\'3fLicensed Research Products.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 26-29. Licensed Products included diagnostic kits 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_352_17}{\*\bkmkend co_pp_sp_7903_352_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*352
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (for determining the presence of EGFR mutations) that would be marketed and sold for commercial use. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 27. Licensed Research Products were limited to diagnostic kits that would be sold for non-commercial, research use only. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 28-29. Under the terms of the License Agreement, Qiagen could only sell Licensed Research Products for non-commercial use until regulatory approval was obtained for commercial use. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 30. Regulatory approval for the test kits was not obtained until July 2013. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 37. Esoterix concedes that prior to regulatory approval and during the term of the License Agreement, Qiagen paid Esoterix royalties for its sales of Licensed Research Products. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 34-
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Esoterix, however, alleges that a substantial number of those sales were impermissibly made for commercial use, rather than solely for research purposes, as required by the License Agreement and the non-exclusive patent rights it granted to Qiagen. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 36, 38.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In Count I of the Amended Complaint, Esoterix alleges that when Qiagen offered for sale and sold those test kits for uses other than those authorized by the License Agreement, Qiagen infringed the claims in Esoterix\rquote s 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 45-54. Esoterix further alleges that Qiagen\rquote s actions induced patent infringement and contributed to infringement by others. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 55-56. In Count II, Esoterix alleges that Qiagen acted in bad faith by offering test kits for commercial use prior to regulatory approval, and thereby violated Massachusetts General Laws Ch. 93A. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 59-70. Count III sets forth a claim for breach of contract, alleging that Qiagen breached the terms of the License Agreement. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 73-77. In Count IV, Esoterix alleges that Qiagen also breached the duty of good faith and fair dealing that arose under the License Agreement. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 79-89. Esoterix claims that it has suffered damages as a result of Qiagen\rquote s actions, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 57-58, 71-72, 78, 90-91, and it seeks compensatory damages, plus certain statutory enhancements, as well as costs and attorneys\rquote  fees.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id83a5471c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id83a5471c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id83a5471c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id83a5471c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
III. THE 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 PATENT
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims a method for \u8220\'3fdetermining an increased likelihood of pharmacological effectiveness of treatment by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in an individual diagnosed with non-small 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic75605b3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
lung cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 519:43-48. The significance of this invention is explained in the patent\rquote s specification. Epithelial cell 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which include 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic30437c8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
non-small cell lung cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, are diseases characterized by abnormal, accelerated growth of epithelial cells. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 1:43-47. Epidermal growth factor receptor (\u8220\'3fEGFR\u8221\'3f), a protein expressed on the surface of those epithelial cells, is the product of a growth-promoting oncogene (erbB or ErbB1). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2:3-17. This oncogene is believed to play a pivotal role in the development of epithelial cell 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2:16-18. Thus, scientists have explored inhibiting EGFR as a method of treating such 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. One area of exploration involves EGFR tyrosine kinase inhibitors. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2:58-3:14. Two of the more advanced compounds in clinical development in this area include 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (developed by AstraZeneca UK Ltd), and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (developed by Genetech, Inc. and OSI Pharmaceuticals). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 3:15-22. The use of the drugs is limited, however, because patients can develop a resistance to their therapeutic effects, and some patients simply do not respond to these drugs at all. As noted in the patent, tyrosine kinase inhibitor therapies, such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, are not effective for the \u8220\'3fvast majority\u8221\'3f of non-small 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic75605b3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
lung cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 3:57-59.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The key discovery made by the inventors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is that the presence of certain mutations in the kinase domain of a patient\rquote s EGFR gene substantially increases the sensitivity of EGFR to tyrosine 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_353_17}{\*\bkmkend co_pp_sp_7903_353_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*353
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 kinase inhibitor therapy. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 3:59-63. By determining whether or not a patient has such mutations in his or her EGFR, a doctor or scientist can predict the likelihood that the patient will respond to tyrosine kinase inhibitor therapies like 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 4:5-8. The abstract of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 describes the invention as a \u8220\'3fmethod for determining the responsiveness of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to an epidermal growth factor receptor (EGFR) treatment.\u8221\'3f Noting that \u8220\'3fthe presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f the abstract explains that a \u8220\'3fdiagnostic assay\u8221\'3f\u8212\'3fi.e., a test\u8212\'3ffor these mutations will allow doctors to administer 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and other inhibitors to those patients most likely to respond to the drugs.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, Claim 1, the only independent claim in the patent, claims
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[a] method for determining an increased likelihood of pharmacological effectiveness of treatment by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in an individual diagnosed with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic30437c8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
non-small cell lung cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Obtaining DNA from a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic30437c8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
non-small cell lung cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 tumor sample from the individual; and determining the presence or absence of at least one nucleotide variance in exon 18, 19, or 21 of the epidermal growth factor receptor (EGFR) gene in the DNA, wherein the presence of at least one nucleotide variance selected from:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1) An in-frame deletion in exon 19 of the EGFR gene consisting of a deletion within codons 746 to 753 that results in amino acid changes comprising a deletion of at least amino acids leucine, arginine, and glutamic acid at position 747, 748, and 749 of SEQ ID NO:512;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
2) A substitution in exon 21 that results in an amino acid change consisting of a substitution of arginine for leucine at position 858 (L858R) of SEQ ID NO:512, or a substitution in exon 21 that results in an amino acid change consisting of a substitution of glutamine for leucine at position 861 (L861Q) of SEQ ID NO:512; or
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3) A substitution in exon 18 that results in an amino acid change consisting of a substitution of cysteine for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=Iffb483c06c7111e18b05fdf15589d8e8&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glycine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 at position 719 (G719C) of SEQ ID NO:512
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
indicates an increased likelihood of pharmacological effectiveness of treatment by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 in the individual.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 519:44\u8211\'3f520:49.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The remaining claims in the patent (Claims 2-8) are all dependent claims incorporating the method of Claim 1, in which the \u8220\'3fdetermining\u8221\'3f step is carried out by specified detection methods (Claims 2-5), or the nucleotide variance is limited to a specified variance (Claims 6-8). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 520:50-522:5.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8421ca1c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8421ca1c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8421ca1c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8421ca1c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
IV. PROCEDURAL HISTORY
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Esoterix filed its Complaint on August 5, 2014, and an Amended Complaint on August 14, 2014. [ECF No. 7.] On October 31, 2014, Qiagen filed its Motion to Dismiss all of Esoterix\rquote s claims, arguing that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid because it purports to patent \u8220\'3flaws of nature,\u8221\'3f which are not patentable subject matter under 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act. [ECF No. 27.] Qiagen further argues that because the Patent is invalid, all of Esoterix\rquote s accompanying state law claims must also be dismissed. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Esoterix filed an Opposition to Qiagen\rquote s Motion to Dismiss on November 25, 2014, [ECF No. 36], and Qiagen filed a Reply on December 15, 2014. [ECF No. 39.] Esoterix filed a Sur-Reply on January 15, 2015, [ECF No. 44], and Qiagen filed a 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_354_17}{\*\bkmkend co_pp_sp_7903_354_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*354
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Sur-Response on January 23, 2015. [ECF No. 47.] On July 6, 2015, Qiagen filed a Notice of Supplemental Authority, alerting the Court to the Federal Circuit\rquote s decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371 (Fed.Cir.2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. [ECF No. 62.] Esoterix filed a Response to this Notice on July 9, 2015. [ECF No. 63.] The parties appeared before the Court for a hearing on Qiagen\rquote s Motion to Dismiss on July 13, 2015. [ECF No. 65.]
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022037262855_ID0EI6AG_17}{\*\bkmkend co_fnRef_B00022037262855_ID0EI6AG_17}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022037262855_17" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id84550f1c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id84550f1c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id84550f1c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id84550f1c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
V. LEGAL STANDARD, RIPENESS, AND BURDENS OF PROOF
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12037262855_17}{\*\bkmkend co_anchor_B12037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To survive a motion to dismiss, a plaintiff must \u8220\'3fstate a claim that is plausible on its face.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_570&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_570" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Bell Atl. Corp. v. Twombly
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fA claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_678&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_678" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ashcroft v. Iqbal
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In this case, however, the critical issue is not whether Esoterix\rquote s Amended Complaint alleges facts sufficient to make out plausible claim for patent infringement. Rather, the key question is whether it is sufficiently clear\u8212\'3fat this early stage of the proceedings\u8212\'3fthat Esoterix\rquote s patent claims fail as a matter of law because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 covers ineligible subject matter, and is therefore invalid. In other words, Qiagen\rquote s Motion to Dismiss has raised an affirmative defense of invalidity. The First Circuit has acknowledged that \u8220\'3f[w]hile most 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motions are premised on a plaintiff\rquote s putative failure to state an actionable claim, such a motion may sometimes be premised on the inevitable success of an affirmative defense.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010604269&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_150&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_150" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Nisselson v. Lernout
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 469 F.3d 143, 150 (1st Cir.2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It is appropriate to allow a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion on the basis of an affirmative defense if: \u8220\'3f(i) the facts establishing the defense are definitively ascertainable from the complaint and the other allowable sources of information, and (ii) those facts suffice to establish the affirmative defense with certitude.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010604269&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2005476035&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_12&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_12" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rodi v. S. New Engl. Sch. Of Law
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 389 F.3d 5, 12 (1st Cir.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22037262855_17}{\*\bkmkend co_anchor_B22037262855_17}
}
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32037262855_17}{\*\bkmkend co_anchor_B32037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Esoterix, however, contends that it would be inappropriate to adjudicate the issue of invalidity at the motion-to-dismiss stage, and it argues that the Court must engage in claim construction before ruling on whether the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 covers eligible subject matter. \u8220\'3fWhether a claim is drawn to patent-eligible subject matter under 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is an issue of law ....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017388082&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_951&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_951" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Bilski
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 545 F.3d 943, 951 (Fed.Cir.2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fAlthough the determination of patent eligibility requires a full understanding of the basic character of the claimed subject matter, claim construction is not an inviolable prerequisite to a validity determination under 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat. Ass\rquote n
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d 1343, 1349 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032785610&pubNum=0006538&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_6538_992&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_992" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Cyberfone Sys., LLC v. CNN Interactive Grp., Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 558 Fed.Appx. 988, 992 n. 1 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThere is no requirement that the district court engage in claim construction before deciding 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 eligibility.\u8221\'3f) (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028287013&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1273&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1273" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Bancorp Servs., L.L.C. v. Sun Life Assur. Co. of Canada (U.S.)
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 687 F.3d 1266, 1273 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Although \u8220\'3fthere may be cases in which the legal question as to patentable subject 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_355_17}{\*\bkmkend co_pp_sp_7903_355_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*355
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 matter may turn on subsidiary factual issues,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017945032&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_975&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_975" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Comiskey
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 554 F.3d 967, 975 (Fed.Cir.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Esoterix has not identified any relevant factual or claim construction issues that would preclude the Court from deciding whether the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 covers eligible subject matter at this stage of the proceedings.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032037262855_ID0EWKBG_17}{\*\bkmkend co_fnRef_B00032037262855_ID0EWKBG_17}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032037262855_17" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42037262855_17}{\*\bkmkend co_anchor_B42037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties also appear to disagree about the legal standard applicable to Qiagen\rquote s Motion to Dismiss. Esoterix contends that Qiagen must prove that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not cover patentable subject matter by \u8220\'3fclear and convincing\u8221\'3f evidence. [ECF No. 36, at 4 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2245&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2245" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Microsoft Corp. v. i4i Ltd. P\rquote ship
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 564 U.S. 91, 131 S.Ct. 2238, 2245, 180 L.Ed.2d 131 (2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).] The clear and convincing standard derives from Section 282 of the Patent Act, which provides that patents issued by the United States Patent and Trademark Office are entitled to a \u8220\'3fpresumption of validity\u8221\'3f when faced with an invalidity challenge from an alleged infringer. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2245&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2245" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Microsoft Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 131 S.Ct. at 2245
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As a result, a party attacking the validity of a patent must generally prove invalidity by clear and convincing evidence. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Qiagen, however, points out that the law is unsettled as to whether the presumption of validity, and, in turn, the \u8220\'3fclear and convincing\u8221\'3f standard, applies when the issue is one of 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 validity. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_720&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_720" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 772 F.3d 709, 720 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Mayer, J., concurring) (concluding that although \u8220\'3fa presumption of validity attaches in many contexts, no equivalent presumption of eligibility applies in the 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 calculus\u8221\'3f) (citation omitted). Lower courts appear to be divided on this issue, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036473917&pubNum=0007903&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Affinity Labs of Texas, LLC v. DirecTV, LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 6:15\u8211\'3fCV\u8211\'3f0030\u8211\'3fWSS\u8211\'3fJCM, 109 F.Supp.3d 916, 2015 WL 3764356, at *16 & n. 6 (W.D.Tex. July 7, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (collecting cases), and there is no binding precedent from the Federal Circuit.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042037262855_ID0ERPBG_17}{\*\bkmkend co_fnRef_B00042037262855_ID0ERPBG_17}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042037262855_17" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_356_17}{\*\bkmkend co_pp_sp_7903_356_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*356
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court, however, need not resolve this question, because the debate over the appropriate burden of proof appears to be purely academic in the context of this case. As noted above, Esoterix has not convincingly identified any factual discovery as necessary to resolve the patentability issue. Furthermore, Qiagen\rquote s Motion to Dismiss does not seek to establish any facts that would be subject to proof by clear and convincing evidence. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2253&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2253" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Microsoft Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 131 S.Ct. at 2253
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Breyer, J., concurring) (noting that the \u8220\'3fclear and convincing\u8221\'3f standard is an \u8220\'3fevidentiary standard of proof\u8221\'3f that \u8220\'3fapplies to questions of fact and not to questions of law\u8221\'3f). Rather, Qiagen argues that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid because it covers ineligible subject matter, and that this can be resolved based on a straightforward application of 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case law to the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035645234&pubNum=0000999&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Modern Telecom Sys. LLC v. Earthlink, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. SA CV 14\u8211\'3f0347\u8211\'3fDOC, 2015 WL 1239992, at *7 (C.D.Cal. Mar. 17, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fBecause, ordinarily, no evidence outside the pleadings is considered in resolving a motion to dismiss or a motion for judgment on the pleadings, it makes little sense to apply a \u8216\'3fclear and convincing evidence\u8217\'3f standard [to] ... such motions.\u8221\'3f) Thus, the patentability issue is a question of law, and the Court will assume all facts alleged by Esoterix to be true, and construe the patent claims in the light most favorable to Esoterix. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Content Extraction & Transmission LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d at 1349
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that district court properly resolved defendant\rquote s motion to dismiss at the pleadings stage, where it was clear that the patent claims were directed to ineligible subject matter, even when construed in a light most favorable to the patentee).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id851fb21c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id851fb21c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id851fb21c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id851fb21c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
VI. DISCUSSION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id851fb21c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id851fb21c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. The Patent Claims (Count I)
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. Patentability Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b1 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
\sa200 
\sb400 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fThe 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}}}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Test
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52037262855_17}{\*\bkmkend co_anchor_B52037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The general standard for patentability is found in 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act, which provides that \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The United States Supreme Court, however, has \u8220\'3flong held that this provision contains an important implicit exception: Laws of nature, natural phenomena, and abstract ideas are not patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice Corp. Pty. v. CLS Bank Int\rquote l
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 2354, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotations and citation omitted). \u8220\'3fPhenomena of nature, though just discovered ... are not patentable, as they are the basic tools of scientific and technological work.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 132 S.Ct. 1289, 1293, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_67&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_67" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Gottschalk v. Benson
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 409 U.S. 63, 67, 93 S.Ct. 253, 34 L.Ed.2d 273 (1972)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Because \u8220\'3fmonopolization of these tools through the grant of a patent might tend to impede innovation more than it would tend to promote it,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo Collaborative Servs.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1293
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the discovery of natural phenomena is generally not amenable to patent protection. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court has also cautioned, however, against \u8220\'3ftoo broad an interpretation of this exclusionary principle.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 If taken to extremes, the \u8220\'3flaw of nature\u8221\'3f principle has the potential to \u8220\'3feviscerate 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_357_17}{\*\bkmkend co_pp_sp_7903_357_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*357
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent law,\u8221\'3f as \u8220\'3fall inventions at some level embody, use, reflect, rest upon, or apply laws of nature.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Often, the line separating the patentable from the unpatentable is very thin. While a \u8220\'3fscientific truth\u8221\'3f may not be a patentable invention, \u8220\'3fan 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
application
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of a law of nature ... to a known structure or process may well be deserving of patent protection.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1293\u8211\'3f94
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But \u8220\'3fto transform an unpatentable law of nature into a patent-eligible 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
application
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of such a law, one must do more than simply state the law of nature while adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62037262855_17}{\*\bkmkend co_anchor_B62037262855_17}
}
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72037262855_17}{\*\bkmkend co_anchor_B72037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court\rquote s recent decisions in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank International
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 establish a two-part test to determine whether patent claims cover eligible subject matter. \u8220\'3fFirst, we determine whether the claims at issue are directed to one of those patent-ineligible concepts [that include the laws of nature, natural phenomena, and abstract ideas].
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fIf so, we then ask, \u8216\'3f[w]hat else is there in the claims before us?\u8217\'3f To answer that question, we consider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo Collaborative Servs.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1296\u8211\'3f97
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). When conducting the second part of this analysis, the court is searching for an \u8220\'3finventive concept,\u8221\'3f i.e., \u8220\'3fan element or combination of elements that is \u8216\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alterations adopted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court\rquote s application of this two-part analysis in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is instructive, as the patent claims in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bear some similarities to the claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Like the claims in this case, the claims in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were method claims. They asserted patent claims on
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[a] method of optimizing therapeutic efficacy for treatment of an immune-mediated 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Icac9cfe6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gastrointestinal disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Icac9cfe6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gastrointestinal disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(b) determining the level of 6-thioguanine in said subject, ...
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein the level of 6-thioguanine less than about 230 pmol per 8x108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein the level of 6-thioguanine greater than about 400 pmol per 8x108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1295" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
132 S.Ct. at 1295
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court held that these claims set forth \u8220\'3flaws of nature\u8221\'3f\u8212\'3fspecifically, \u8220\'3frelationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of thiopurine drug will prove ineffective or cause harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1296
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This relationship, the Court noted, \u8220\'3fis a consequence of the ways in which thiopurine compounds are metabolized by the body\u8212\'3fentirely natural processes.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court concluded that where the claims \u8220\'3fsimply describes that relation,\u8221\'3f the claims were directed to a natural law. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Next, the Court tested whether the claims did \u8220\'3fsignificantly more than simply describe these natural relations,\u8221\'3f\u8212\'3fmore 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_358_17}{\*\bkmkend co_pp_sp_7903_358_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*358
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 precisely, whether the claims \u8220\'3fadd 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
enough
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to their statements of the [natural] correlations to allow the processes they describe to qualify as patent-eligible processes that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
apply
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 natural laws?\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Specifically, the Court analyzed the \u8220\'3fadministering,\u8221\'3f \u8220\'3fdetermining,\u8221\'3f and \u8220\'3fwherein\u8221\'3f steps in the patent claims to determine whether they were sufficient to \u8220\'3ftransform the nature of the claim\u8221\'3f from a law of nature into a novel invention worthy of patent protection. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Court first found that, considered individually, none of these steps (administering, determining, wherein) added anything transformative to the basic law of nature recited in the claim. The Court noted that \u8220\'3fthe \u8216\'3fwherein\u8217\'3f clauses simply tell a doctor about the relevant natural laws, at most adding a suggestion that he should take those laws into account when treating his patient.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Further, the \u8220\'3fdetermining\u8221\'3f step instructed the doctor to measure the metabolite levels in the blood, \u8220\'3fthrough whatever process the doctor or the laboratory wishes to use.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In fact, the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patents themselves admitted that methods for determining metabolite levels were already well-known in the art. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297\u8211\'3f98
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fPurely conventional or obvious pre-solution activity is normally not sufficient to transform an unpatentable law of nature into a patent-eligible application of such a law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_590&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_590" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Parker v. Flook
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 U.S. 584, 590, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Similarly, the \u8220\'3fadministering\u8221\'3f clause did not add anything inventive to the claims; it simply referred to the relevant audience (doctors), who had been using thiopurine drugs \u8220\'3fto treat patients suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39e7bac475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
autoimmune disorders
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 long before anyone asserted these claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, none of the additional steps, considered individually, added any innovation worthy of patent protection to the basic law of nature that was recited in the claims. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Second, the
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Court considered whether the combination of these three steps into a discrete process added anything novel to the law of nature recited in the claims. The Court found that nothing about the combination of these three steps added anything to the law of nature \u8220\'3fthat is not already present when the steps are considered separately.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In sum, \u8220\'3fthe claims inform a relevant audience about certain laws of nature; any additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community; and those steps, when viewed as a whole, add nothing significant beyond the sum of their parts.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court ultimately concluded that because the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patents \u8220\'3feffectively claim the underlying laws of nature themselves,\u8221\'3f and were not sufficiently transformative to warrant patent protection, the patent claims were drawn to ineligible subject matter, and were therefore invalid. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1305&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1305" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1305
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id8605301c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id8605301c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. Application of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}}}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82037262855_17}{\*\bkmkend co_anchor_B82037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court agrees with Qiagen that, under the two-part test set forth in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, much like the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patents, are ineligible for patent protection. First, Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to a law of nature, in that it describes the correlation between a naturally-occurring mutation in a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 cell, and the likelihood that a particular type of known pharmaceutical compound will be effective in treating that type of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 concedes that the use of EGFR tyrosine kinase inhibitors like 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as a treatment for epithelial 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was already well-known in the art at the time of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 application. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2:58-3:
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The inventors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not invent a new treatment for such 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, or fundamentally alter an existing treatment. Rather, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_359_17}{\*\bkmkend co_pp_sp_7903_359_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*359
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 they discovered why a known treatment was more effective in treating some patients than in others. Although the discovery is significant, the correlation between the naturally-occurring gene mutation they identified, and the effectiveness of a known treatment method, is a \u8220\'3fnatural process,\u8221\'3f and an \u8220\'3feternal truth that exists in principal apart from any human action.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029241057&pubNum=0006538&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_6538_70&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_70" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
PerkinElmer, Inc. v. Intema Ltd.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 496 Fed.Appx. 65, 70 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Therefore, Claim 1 is directed to a law of nature.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Second, the Court finds nothing \u8220\'3ftransformative\u8221\'3f in the method of Claim 1 that amounts to a novel application of the natural law, or that otherwise warrants patent protection. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2354\u8211\'3f55
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Individually, none of the steps comprising the method in Claim 1 is novel or transformative. First, the \u8220\'3fobtaining\u8221\'3f step of \u8220\'3f[o]btaining DNA from a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic30437c8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
non-small cell lung cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 tumor sample from the individual[,]\u8221\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 519:49-50, is not inventive. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 14:20-24 (\u8220\'3fNucleic acid molecules can be isolated from a particular biological sample using any number of procedures which are well-known in the art ....\u8221\'3f) Similarly, the \u8220\'3fdetermining\u8221\'3f step relies upon known methods of detecting genetic mutations. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 14:32-44 (\u8220\'3fDetermining the presence or absence of a particular variance or plurality of variances in the kinase domain of the erbB1 gene in a patient can be performed in a variety of ways.\u8221\'3f), 15:24-33 (\u8220\'3fMethods for diagnostic tests are well known in the art and disclosed in patent application WO 00/04194, incorporated herein by reference.\u8221\'3f). Finally, the \u8220\'3fwherein\u8221\'3f step simply recites the natural law in question\u8212\'3fthat the presence of at least one identified genetic variance set forth in Claim 1 \u8220\'3findicates an increased likelihood of pharmacological effectiveness of treatment by gefitinib or erlotinib in the individual.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 519:53-520:49.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Esoterix argues that together, these steps comprise a method that is novel and transformative, because \u8220\'3f[t]he correlation between these particular nucleotide variances and gefitinib and erlotinib was not previously known or understood, and thus, it was not routine or conventional to administer these drugs when those nucleotide variances were present.\u8221\'3f [ECF No. 36, at 9.] Esoterix nonetheless concedes that conventional treatment for epithelial 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 already included EGFR tyrosine kinase inhibitors such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af158bd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gefitinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2c8f1475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
erlotinib
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. [
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4]; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2:58-3:
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Therefore, Esoterix, in essence, is claiming that it was not previously conventional to administer these drugs 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
only
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to patients with these particular genetic mutations. Because the correlation identified by Esoterix was not previously known, the drugs were, instead, prescribed more indiscriminately. Thus, the method claimed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not fundamentally transform, or even alter, a known method of treating these 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, it identifies a law of nature that explains why such treatment is more effective in a certain population of patients, and tells scientists and doctors that they can \u8220\'3fapply\u8221\'3f that law of nature by testing for the relevant gene mutations using methods well-known in the art. Although the additional steps are \u8220\'3fnot themselves natural laws,\u8221\'3f \u8220\'3fneither are they sufficient to transform the nature of the claim.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Consequently, the Court finds that, much like the claims analyzed in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to ineligible subject matter, and is therefore invalid.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052037262855_ID0EDHBI_17}{\*\bkmkend co_fnRef_B00052037262855_ID0EDHBI_17}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052037262855_17" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_360_17}{\*\bkmkend co_pp_sp_7903_360_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*360
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371 (Fed.Cir.2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Federal Circuit in invalidating a patent directed to a natural phenomenon held that, \u8220\'3fappending routine, conventional steps to a natural phenomenon, specified at a high level of generality, is not enough to supply an inventive concept\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Assoc. for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 689 F.3d 1303, 1334 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that claims \u8220\'3fcomparing\u8221\'3f or \u8220\'3fanalyzing\u8221\'3f two gene sequences to determine variances were unpatentable because they claimed only \u8220\'3fabstract mental processes\u8221\'3f of comparing two genetic sequences to determine if the two \u8220\'3fare the same or different, wherein the later indicates an alteration ....\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029241057&pubNum=0006538&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_6538_66&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_66" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
PerkinElmer v. Intema
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 496 Fed.Appx. 65, 66\u8211\'3f73 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that a method of measuring levels of certain biomarkers from pregnancy to determine whether there was an increased risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibc288ad2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Down\rquote s syndrome
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was unpatentable, because the relationship between the bio-markers and the risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibc288ad2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Down\rquote s syndrome
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is \u8220\'3fa natural process, an eternal truth,\u8221\'3f and the steps of \u8220\'3fmeasuring\u8221\'3f the markers or \u8220\'3fdetermining\u8221\'3f the increased risk were methods stated as \u8220\'3fknown\u8221\'3f in the patent\rquote s specification); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034293397&pubNum=0000999&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Laboratory Corp. of Am. Holdings
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 12\u8211\'3f1736\u8211\'3fLPS\u8211\'3fCJB, 2014 WL 4379587, at *10 (D.Del. Sept. 3, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that a method of analyzing a human sample to detect the presence of certain genetic variations, and linking that variation with a resulting physical condition, was an unpatentable natural law).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This holding also extends to each of the dependent claims in Claims 2-8. A dependent claim necessarily includes all limitations from the independent claim upon which it relies, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112(d)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the dependent claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 do not purport to add any further limitations that would qualify independently for patent protection. Claims 2, 3, 4, and 5 claim the method of Claim 1, wherein the presence or absence of the identified mutations are determined by \u8220\'3fDNA sequencing\u8221\'3f (Claim 2); \u8220\'3fallele-specific amplification\u8221\'3f (Claim 3); \u8220\'3fsingle strand conformation polymorphism, denaturing gradient gel electrophoresis or temperature gradient gel electrophoresis analysis\u8221\'3f (Claim 4); and \u8220\'3fmismatch cleavage analysis.\u8221\'3f (Claim 5). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 520:50-63. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, in fact, concedes that each of these methods was well-known in the art, and Esoterix does not now argue otherwise. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 468 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 14:32-43 (noting that tests for determining the presence of variances are \u8220\'3fcommonly performed\u8221\'3f and \u8220\'3fcan be performed by a variety of methods\u8221\'3f); 23:63-67 (noting that nucleic acid sequencing \u8220\'3fcan be carried out by various methods recognized by those skilled in the art\u8221\'3f); 18:56-65 (describing allele specific amplification and citing sources); 18:12-17 (describing use of single strand conformation polymorphism and citing sources); 17:39-49 (describing the \u8220\'3fart technique\u8221\'3f of mismatch cleavage analysis). Therefore, Claims 2-5 are also directed to ineligible subject matter. Similarly, Claims 6, 7, and 8 claim the method of Claim 1, wherein the nucleotide variance is limited to a specific mutation. Again, there is nothing inventive added by these limitations, and therefore, Claims 6-8 are also directed to ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In light of this conclusion, the Court need not address Qiagen\rquote s alternative argument that Esoterix\rquote s claims for indirect infringement should be dismissed for failure to plead facts sufficient to make out a plausible claim for relief. [ECF No. 27, at 15-17.] In the absence of any valid patent claims, all of Esoterix\rquote s patent infringement 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_361_17}{\*\bkmkend co_pp_sp_7903_361_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*361
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims in Count I of the Amended Complaint are hereby 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DISMISSED
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id86a3e11c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id86a3e11c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. The State-Law Claims (Counts II\u8211\'3fIV)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92037262855_17}{\*\bkmkend co_anchor_B92037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Qiagen next argues that if Esoterix\rquote s patent claims are invalid, Esoterix\rquote s accompanying state-law claims for breach of contract, violation of M.G.L. c. 93A, and breach of the covenant of good faith and fair dealing must be dismissed as well. The premise of Qiagen\rquote s argument, however, is that Esoterix\rquote s claim for breach of contract is entirely coextensive with Esoterix\rquote s patent infringement claim. According to Qiagen, the only difference between the patent and contract claims is that in Count III, Esoterix is \u8220\'3fenforcing Qiagen\rquote s promise not to infringe the patent,\u8221\'3f rather than enforcing the patent itself. Qiagen argues that where the underlying patent has been invalidated, the corresponding \u8220\'3fpromise not to infringe\u8221\'3f is unenforceable in a breach of contract action. [ECF No. 27, at 17.]
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To support this argument, Qiagen relies on a line of cases beginning with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear, Inc. v. Adkins
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 395 U.S. 653, 89 S.Ct. 1902, 23 L.Ed.2d 610 (1969)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, in which the Supreme Court abolished the rule of licensee estoppel. Before 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was decided, a licensee could be estopped from arguing that the patent was invalid, as a defense in a suit for unpaid royalties. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_656&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_656" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 395 U.S. at 656, 89 S.Ct. 1902
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1950116135&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_836&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_836" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Automatic Radio Mfg. Co. v. Hazeltine Research
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 339 U.S. 827, 836, 70 S.Ct. 894, 94 L.Ed. 1312 (1950)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court explained that the doctrine of licensee estoppel was the result of applying \u8220\'3fordinary contract principles\u8221\'3f to a patent licensing agreement. Typically, by \u8220\'3faccepting a license and paying royalties,\u8221\'3f the licensee \u8220\'3freceives certain benefits.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 669, 89 S.Ct. 1902
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As examples, the licensee has \u8220\'3favoided the necessity of defending an expensive infringement action,\u8221\'3f and the \u8220\'3fexistence of an unchallenged patent may deter others from attempting to compete with the licensee.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court acknowledged that under contract law, \u8220\'3fthe mere fact that some benefit is received is enough to require the enforcement of the contract, regardless of the validity of the underlying patent.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Nonetheless, the Court held that in patent cases, this principle of contract law must yield to federal patent policy, which would be frustrated if licensees were prevented from challenging a patent\rquote s validity. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 670\u8211\'3f71, 89 S.Ct. 1902
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court pointed out that licensees \u8220\'3fmay often be the only individuals with enough economic incentive to challenge the patentability of an inventor\rquote s discovery.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 670, 89 S.Ct. 1902
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fIf they are muzzled, the public may continually be required to pay tribute to would-be monopolists without need or justification.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Therefore, in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court held that a licensee is not estopped from challenging the validity of a patent, because the \u8220\'3ftechnical requirements of contract doctrine must give way\u8221\'3f to federal patent policy. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 670\u8211\'3f71, 89 S.Ct. 1902
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102037262855_17}{\*\bkmkend co_anchor_B102037262855_17}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 however, does not hold that a licensee is retroactively absolved of all contractual liability if the underlying patent is invalidated. In fact, it is well-established that a licensor may pursue a licensee for breach of contract, notwithstanding the invalidity of an underlying patent. For example, in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Studiengesellschaft Kohle, M.B.H. v. Shell Oil Co.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 112 F.3d 1561 (Fed.Cir.1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit held that a licensee remains liable for unpaid royalties under a license agreement, up until the date that the licensee first challenges the validity of the claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1567&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1567" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
112 F.3d at 1567\u8211\'3f68
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Shell Oil
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a patent holder and licensor brought claims against a licensee for (1) unpaid royalties under a license agreement, and (2) patent infringement. After finding that several of the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_362_17}{\*\bkmkend co_pp_sp_7903_362_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*362
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent claims were invalid, the district court held that the licensor could, nonetheless, recover damages for breach of the license agreement, \u8220\'3fwhere the validity of the underlying patent was not challenged until after the breach occurred.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1563&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1563" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1563
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court also certified a question to the Federal Circuit, namely, whether the subsequent invalidation of the patent would affect the licensor\rquote s claims for unpaid royalties for the period before the licensee challenged the validity of the patent. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1563&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1563" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1563\u8211\'3f64
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit held that it would not. In so holding, the court noted that \u8220\'3fcontract law governs the enforcement of the license,\u8221\'3f and \u8220\'3f[n]othing in [the] license made payment of royalties contingent upon the validity of [the patent-in-suit].
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1567&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1567" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1567
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit, consistent with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 acknowledged that principles of state contract law may be overridden when federal patent policies would be \u8220\'3fsignificantly frustrated\u8221\'3f by enforcing a licensing agreement, but found \u8220\'3fno significant frustration of federal patent policy by enforcing the [license agreement], to the extent of allowing [the licensor] to recover royalties until the date [licensee] first challenged the validity of the claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1568&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1568" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1568
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1988073214&pubNum=0000350&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Diamond Scientific Co. v. Ambico, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 848 F.2d 1220 (Fed.Cir.1988)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The court reasoned that the licensee derived significant benefits from the licensing agreement\u8212\'3fnamely, insulation from competition and protection against infringement accusations. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Accordingly, permitting the licensee to \u8220\'3fexploit the protection of the contract and patent rights and then later to abandon conveniently its obligations under those same rights\u8221\'3f would be manifestly unjust. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, the Federal Circuit held that a licensee cannot invoke the protection of the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 doctrine until it \u8220\'3f(i) actually ceases payment of royalties, and (ii) provides notice to the licensor that the reason for ceasing payment of royalties is because it has deemed the relevant claims to be invalid.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998164899&pubNum=0004637&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_4637_180&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_180" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Wang Labs., Inc. v. Oki Elec. Indus. Co., Ltd.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 15 F.Supp.2d 166, 180 (D.Mass.1998)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (royalties are due under a patent licensing agreement until the licensee gives notice that it is challenging the validity of the patents); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980102421&pubNum=0000350&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_350_896&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_896" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Am. Sterilizer Co. v. Sybron Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 614 F.2d 890, 896 (3d Cir.1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fHence, despite the patent\rquote s invalidity, [plaintiff] had a contract claim against [its licensee] enforceable until the initiation of the lawsuit\u8221\'3f challenging the validity of the patent); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028323712&pubNum=0000999&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Advocent Redmond Corp. v. Raritan Americas, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 10\u8211\'3fcv\u8211\'3f6100 PKC, 2012 WL 3114855, at *12 (S.D.N.Y. July 31, 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3finvalidity of the asserted patents will not absolve [a licensee] of any liability it has for breach of contract\u8221\'3f prior to its challenge to the validity of the patents).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112037262855_17}{\*\bkmkend co_anchor_B112037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Qiagen argues that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Shell Oil
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and its progeny are distinguishable because they relate to the licensor\rquote s right to recover 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
royalties
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 due, and here, Esoterix does not seek unpaid royalties. Even assuming that no royalties are sought, the Court is not persuaded that there is a relevant distinction between unpaid royalties and other types of damages flowing from the breach of the Licensing Agreement. The Federal Circuit\rquote s holding in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Shell Oil
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not obviously limited to royalties and can be read to stand for the broader principle that a licensee may not avoid liability for 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
damages
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 arising out of its breach of a license agreement, assuming that the breach occurred prior to the date that the licensee first challenged the validity of the patent claims. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1568&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1568" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
112 F.3d at 1568
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Consistent with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Shell Oil
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to the extent that Qiagen owes Esoterix any additional payments for its unauthorized sales, those royalties may be recoverable under a breach of contract theory, up until the point when Qiagen formally challenged the patent\rquote s validity. Further, to the extent 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_363_17}{\*\bkmkend co_pp_sp_7903_363_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*363
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that Qiagen\rquote s breach caused Esoterix to incur any other type of damages, Esoterix may also pursue such damages under a breach of contract theory. The invalidity of the patent does not, as Qiagen contends, automatically foreclose Esoterix\rquote s breach of contract claim. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004531927&pubNum=0004637&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_4637_1027&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_1027" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Hoffman\u8211\'3fLa Roche, Inc. v. Promega Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 319 F.Supp.2d 1011, 1027\u8211\'3f28 (N.D.Cal.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (rejecting defendant\rquote s argument that patent\rquote s invalidity warranted dismissal of all contract claims).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&pubNum=0000350&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Furthermore, Qiagen\rquote s reliance on the Ninth Circuit\rquote s 1971 decision in 
}
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Massillon\u8211\'3fCleveland\u8211\'3fAkron Sign Co. v. Golden State Advert. Co.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 444 F.2d 425 (9th Cir.1971)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, is misplaced. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Massillon
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the parties had previously settled a patent infringement dispute. In the relevant settlement agreement, the alleged infringers expressly acknowledged the validity of the patent, covenanted not to contest the patent\rquote s validity, and further agreed that they would not infringe the patent in the future. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&pubNum=0000350&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_350_425&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_425" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
444 F.2d at 425
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. After the settlement agreement was executed, however, the patent holder learned that the alleged infringers were, once again, infringing on the patent. The patent holder brought suit against the infringers and other third parties, alleging that they had breached the settlement agreement by infringing the patent, and that the third parties had induced this breach. The Ninth Circuit, relying on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 held that the covenant not to challenge the validity of the patent was unenforceable as contrary to federal patent policy. The court went on, however, to hold that, in the absence of a valid patent, the patent holder was also precluded from pursuing the defendants under a breach of contract theory, because \u8220\'3fa valid patent is a prerequisite to recovery for inducing the breach of a contract not to infringe, as well as a prerequisite to recovery for the breach itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&pubNum=0000350&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_350_428&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_428" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 428
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court finds that the holding in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Massillon
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is inapposite to the facts presented in this case. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Massillon
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the court was not faced with an alleged breach of a licensing agreement. The only promise that was breached was an express and specific covenant not to infringe on the patent claims. Further, this promise had been extracted through a settlement agreement. Therefore, it was clear that the sole factual premise for the breach of contract claim alleged in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Massillon
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was the patent infringement itself. Here, in contrast, Esoterix alleges that Qiagen breached a Licensing Agreement\u8212\'3fa comprehensive agreement setting forth a variety of rights, obligations, and terms and conditions governing an ongoing commercial relationship. Qiagen allegedly breached the Licensing Agreement by, inter alia, offering and selling Licensed Products for commercial use prior to regulatory approval. Particularly in the context of a licensing relationship, it is easy to see how breaching such a promise potentially gives rise to a free-standing contract claim, regardless of whether or not such a breach would also support a claim for patent infringement. Thus, unlike 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1971110990&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Massillon
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the two claims for relief do not necessarily rise or fall together. To hold otherwise would be to ignore the rationale and holding in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Shell Oil
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and permit licensees to \u8220\'3fexploit the protection of the contract and patent rights and then later to abandon conveniently its obligation under those same rights.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997103465&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1568&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1568" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
112 F.3d at 1568
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thus, the Court finds that Esoterix has pled a plausible claim for breach of contract, notwithstanding the ineligibility of the patent claims. Following discovery, the parties can address the issue of what damages are recoverable for the alleged breach. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1989144960&pubNum=0000350&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_350_1064&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1064" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
RCA Corp. v. Data Gen. Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.2d 1056, 1064 (Fed.Cir.1989)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not \u8220\'3fdictate what 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
must
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 be held a breach of contract, or what 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_364_17}{\*\bkmkend co_pp_sp_7903_364_17}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*364
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 damages 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
must
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 be awarded for a breach, or under what circumstances, if any, a licensee can recover royalties paid. Those questions ... [are] dependent on particular fact situations, contract provisions and state contract law, albeit they must be resolved in harmony with general principles discernible from 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1969133016&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Lear
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f), 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
overruled on other grounds,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
as recognized in
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002035706&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Linear Tech. Corp. v. Micrel, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 275 F.3d 1040, 1048 (Fed.Cir.2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, Qiagen\rquote s Motion to Dismiss is 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DENIED
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as to Count III of the Amended Complaint.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122037262855_17}{\*\bkmkend co_anchor_B122037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Esoterix also has claims for breach of the covenant of good faith and fair dealing (Count IV) and violation of Massachusetts General Laws Ch. 93A (Count II), which Qiagen has moved to dismiss. Because the Court has held that the parties\rquote  contractual duties and liabilities may survive the patent\rquote s invalidity, and the implied covenant of good faith and fair dealing is \u8220\'3fas broad as the contract that governs the particular relationship,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006193259&pubNum=0000578&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_578_683&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_578_683" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ayash v. Dana\u8211\'3fFarber Cancer Inst
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
., 443 Mass. 367, 822 N.E.2d 667, 683 (2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Esoterix\rquote s good faith and fair dealing claim is still viable. Qiagen\rquote s Motion to Dismiss is 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DENIED
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as to Count III of the Amended Complaint.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132037262855_17}{\*\bkmkend co_anchor_B132037262855_17}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, Qiagen has asserted no valid grounds for dismissing Esoterix\rquote s Chapter 93A claim. Massachusetts General Laws Ch. 93A is a statute that creates \u8220\'3fbroad new rights, forbidding conduct not previously unlawful under the common law of contract and tort or under any prior statute.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997109869&pubNum=0000521&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_521_27&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_521_27" }{\fldrslt 
{\b0 \cf28 \f2 \i0 \fs20 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Linkage Corp. v. Trustees of Boston Univ.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 425 Mass. 1, 27, 679 N.E.2d 191 (1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotations and citation omitted). Notably, \u8220\'3f[a] determination that conduct is unfair or deceptive is not dependent on traditional tort or contract theories.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997109869&pubNum=0000521&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Here, Esoterix has alleged sufficient facts to make out a plausible claim that Qiagen\rquote s conduct amounted to unfair or deceptive trade practices, and that Esoterix was injured as a result. Consequently, Qiagen\rquote s Motion to Dismiss Count II of the Amended Complaint is 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DENIED
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id87a43a1c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id87a43a1c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Id87a43a1c12a11ea81dd9e3bc3f36}{\*\bkmkend co_anchor_Id87a43a1c12a11ea81dd9e3bc3f36}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
VII. CONCLUSION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, Qiagen\rquote s Motion to Dismiss the Amended Complaint [ECF No. 26] is hereby 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
ALLOWED
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as to Count I, and 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DENIED
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as to all other Counts of the Amended Complaint.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
SO ORDERED.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_17}{\*\bkmkend co_allCitations_17}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
133 F.Supp.3d 349
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012037262855_17}{\*\bkmkend co_footnote_B00012037262855_17}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012037262855_ID0EYEAG_17" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Although the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 468 Patent
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is not physically attached to Esoterix\rquote s Complaint, the Court takes judicial notice of its contents, as the patent is specifically referenced in Esoterix\rquote s Complaint, and it is a matter of public record. 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\b0 \cf1 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1993214170&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_954&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_954" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Hoganas AB v. Dresser Indus., Inc.
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 9 F.3d 948, 954 n. 27 (Fed.Cir.1993)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000607&cite=USFRER201&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Fed. R. Evid. 201(b)(2)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
). A copy of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 468 Patent
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is attached as Exhibits A and B to Qiagen\rquote s Memorandum in Support of its Motion to Dismiss. [ECF Nos. 27-1, 27-2.]
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022037262855_17}{\*\bkmkend co_footnote_B00022037262855_17}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022037262855_ID0EI6AG_17" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
This matter was originally assigned to Judge Sorokin in August 2014, who referred the case to Magistrate Judge Bowler. [ECF No. 4.] In February 2015, the matter was randomly reassigned to my docket. [ECF No. 49.] In March 2015, during a hearing on the Motion to Dismiss, Magistrate Judge Bowler determined that she needed to recuse herself. [ECF No. 54.] I elected not to refer the Motion to an alternative magistrate judge and scheduled a hearing on the Motion. [ECF No. 64.]
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032037262855_17}{\*\bkmkend co_footnote_B00032037262855_17}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032037262855_ID0EWKBG_17" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In fact, most of the \u8220\'3fclaim construction\u8221\'3f issues identified by Esoterix in its Opposition, [ECF No. 36, at 12], are not claim construction issues at all. To the extent that Esoterix proposes particular constructions of terms in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013997511&pubNum=0004074&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=PA&docFamilyGuid=I69961ee4920511dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 468 Patent
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, the Court, as it must, adopts those constructions for purposes of deciding Qiagen\rquote s Motion to Dismiss.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042037262855_17}{\*\bkmkend co_footnote_B00042037262855_17}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042037262855_ID0ERPBG_17" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In 2013, the Federal Circuit stated in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030821372&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1339&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1339" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 722 F.3d 1335, 1339 (Fed.Cir.2013)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030821372&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial I
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8221\'3f) that in order to grant a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Rule 12(b)(6)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 motion on the grounds of ineligible subject matter, \u8220\'3fthe 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\b0 \cf1 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
only
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 plausible reading of the patent must be that there is clear and convincing evidence of ineligibility.\u8221\'3f
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030821372&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_1339&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1339" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
722 F.3d at 1339
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The Supreme Court, however, subsequently vacated the decision in 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030821372&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial I
}\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 }}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and remanded the case for further consideration in light of the Supreme Court\rquote s ruling in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Alice Corp. Pty. v. CLS Bank Int\rquote l
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 189 L.Ed.2d 296 (2014)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\b0 \cf1 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031350142&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
WildTangent, Inc. v. Ultramercial, LLC
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2870, 189 L.Ed.2d 828 (2014)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (granting petition for writ of certiorari, and remanding case to Federal Circuit). Thus, the opinion issued in 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030821372&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial I
}\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 }}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 no longer has precedential effect. 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\b0 \cf1 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034709977&pubNum=0007903&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_7903_527&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_527" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Genetic Techs. Ltd. v. Bristol\u8211\'3fMyers Squibb Co.
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 72 F.Supp.3d 521, 527 (D.Del.2014)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1979108052&pubNum=0000780&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_780_634&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_634" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Los Angeles Cnty. v. Davis
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 440 U.S. 625, 634 n.6, 99 S.Ct. 1379, 59 L.Ed.2d 642 (1979)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
). Furthermore, after the case was remanded, and the Federal Circuit reconsidered the validity issue in light of 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\b0 \cf1 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, the Federal Circuit affirmed the district court\rquote s ruling that the patent was directed to ineligible subject matter, and held that the patent claims were properly dismissed for failure to state a claim. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_716&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_716" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 772 F.3d 709, 716-17 (Fed.Cir.2014)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial II
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8221\'3f), 
}
{\b0 \cf1 \f3 \i0 \fs18 
{\b0 \cf1 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
cert. denied sub nom.
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035824502&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial, LLC v. WildTangent, Inc.
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 192 U.S. 929, 135 S.Ct. 2907, \u8211\'3f\u8211\'3f\u8211\'3f L.Ed.2d \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f (2015)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. Notably, the Federal Circuit\rquote s opinion on remand made no mention of any presumption of validity attaching in a case under 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Section
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
; nor did it mention a clear and convincing evidence standard. But, in a concurring opinion, Judge Mayer opined that \u8220\'3fno presumption of eligibility should attach when assessing whether claims meet the demands of 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
section
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_506_720&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_720" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ultramercial II
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 772 F.3d at 720 (Fed.Cir.2014)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Mayer, J., concurring). Therefore, it is unclear, if there is a presumption of validity or if the clear and convincing evidence standard applies in 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Section
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 challenges.
\par 
}
}
}
}
}\b0 \cf1 \f3 \strike0 \i0 \fs18 \sa0 \sb0 \ri0 \ul0 \qj \li0 \chcbpat2 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052037262855_17}{\*\bkmkend co_footnote_B00052037262855_17}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052037262855_ID0EDHBI_17" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In so holding, the Court does not mean to minimize the importance of the inventors\rquote  discovery. But, \u8220\'3f[g]roundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf28 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \i0 \fs18 \chcbpat29 
{\b1 \cf21 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf28 \f3 \i0 \fs18 \chcbpat2 
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 inquiry.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I02566100668f11e5a966f97caf3cb288&refType=RP&fi=co_pp_sp_708_2117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2117" }{\fldrslt 
{\b0 \cf28 \f3 \i0 \fs18 
{\b0 \cf28 \f3 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Ass\rquote n for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 133 S.Ct. 2107, 2117, 186 L.Ed.2d 124 (2013)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf24 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf24 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf24 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf24 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf24 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf24 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf24 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf24 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }